Vaxcyte, Inc. (PCVX) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PCVX Revenue Growth
Revenue Breakdown (FY 2021)
PCVX's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
PCVX Revenue Analysis (2017–2025)
As of May 8, 2026, Vaxcyte, Inc. (PCVX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, PCVX's historical revenue data shows various trends over time.
Revenue diversification analysis shows PCVX's business is primarily driven by Pneumococcal Conjugate Vaccine (100%). With over half of revenue concentrated in Pneumococcal Conjugate Vaccine, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PFE (+1.4% YoY), MRK (+1.2% YoY), and GSK (+5.4% YoY). Compare PCVX vs PFE →
PCVX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PCVXCurrent | $0 | - | - | - | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 GSK | $32.7B | +5.4% | +6.0% | 25.5% | |
 SNY | $46.7B | +14.1% | +4.6% | 13.6% | |
 BNTX | $2.8B | +4.0% | +41.7% | -22.6% |
PCVX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-923,675,000 | - |
| 2024 | $0 | - | $0 | - | $-569,546,000 | - |
| 2023 | $0 | - | $0 | - | $-468,041,000 | - |
| 2022 | $0 | - | $0 | - | $-232,256,000 | - |
| 2021 | $0 | - | $0 | - | $-103,670,000 | - |
| 2020 | $0 | - | $-1,405,000 | - | $-89,581,000 | - |
| 2019 | $0 | - | $-1,232,000 | - | $-54,153,000 | - |
| 2018 | $0 | - | $-1,037,000 | - | $-35,533,000 | - |
| 2017 | $0 | - | $0 | - | $-17,833,000 | - |
See PCVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCVX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCVX — Frequently Asked Questions
Quick answers to the most common questions about buying PCVX stock.
Is PCVX's revenue growth accelerating or slowing?
PCVX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is PCVX's long-term revenue growth rate?
Vaxcyte, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is PCVX's revenue distributed by segment?
PCVX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.